JupiteX Get the app
Health & Medicine21 Nov 2026 · about 6 min

Promoting protein powders? Tukaram Mundhe’s FDA warns influencers of ₹10 lakh fine over unauthorised promos

The brief

The FDA’s order bars health supplement advertisements from presenting products as treatments or preventives for disease. It also prohibits claims that products can cure or mitigate disease. These rules matter because such messages can mislead consumers about what supplements can do. The order also bans promotional claims that a product is “recommended by doctors or nutritionists.” Advertisements cannot use photographs of physicians or say products are clinically prescribed. These restrictions apply alongside the ban on disease-related claims, rather than only to one kind of product. The order took immediate effect across Maharashtra and covers businesses throughout the supply chain. Misleading advertisements can attract a penalty of up to ₹10 lakh. The FDA is also planning further risk-based inspections, with attention to categories including sports nutrition, weight-loss and herbal products. The article does not describe a separate exemption for online promotions.

01

What kinds of claims and endorsements has Maharashtra’s FDA prohibited in ads for health supplements?

The FDA’s order bars health supplement advertisements from presenting products as treatments or preventives for disease. It also prohibits claims that products can cure or mitigate disease. These rules matter because such messages can mislead consumers about what supplements can do.

The order also bans promotional claims that a product is “recommended by doctors or nutritionists.” Advertisements cannot use photographs of physicians or say products are clinically prescribed. These restrictions apply alongside the ban on disease-related claims, rather than only to one kind of product.

The order took immediate effect across Maharashtra and covers businesses throughout the supply chain. Misleading advertisements can attract a penalty of up to ₹10 lakh. The FDA is also planning further risk-based inspections, with attention to categories including sports nutrition, weight-loss and herbal products. The article does not describe a separate exemption for online promotions.

02

Who must follow the order, and what is the maximum fine for a misleading advertisement?

Maharashtra’s order applies across the supply chain for health supplements, nutraceuticals and special dietary foods. It covers manufacturers, importers, distributors, retailers, pharmacies, gyms and e-commerce platforms. The broad scope means that selling or promoting these products is not limited to manufacturers’ responsibilities.

The FDA has set a maximum penalty of ₹10 lakh for misleading advertisements. Separately, carrying on a food business without the required licence can also draw a penalty of up to ₹10 lakh. The two penalties address different violations, so the amount for misleading ads should not be confused with the licensing penalty.

The order took immediate effect. Businesses making or selling these products must obtain the relevant FSSAI licence and ensure the specific food category is endorsed on it. Pharmacies and gyms need a food licence or registration even if they already hold licences under other laws. The FDA plans further risk-based inspections, including online sales.

03

How much stock did the FDA seize, and how many establishments did it inspect?

Maharashtra’s FDA seized stock worth ₹1,38,95,852 in an enforcement drive focused on health supplements and related products. The seizure total shows the scale of the inspections, but the article does not say that every seized product was confirmed to be unsafe or misbranded.

The inspections took place on November 13 at 17 establishments across six divisions. The FDA reported finding manufacturers using Magnesium Acetyl Taurate and Nicotinamide Mononucleotide, ingredients whose product-approval applications had been rejected by FSSAI. Samples were sent to laboratories for analysis because of suspicions that products were substandard, unsafe or misbranded.

Nagpur recorded the largest seizure, worth ₹57.30 lakh, followed by Konkan at ₹47.65 lakh and Pune at ₹30.57 lakh. The FDA said further legal action would follow receipt of the food analyst’s report. No seizure was reported in Amravati, while smaller amounts were seized in Nashik and Chhatrapati Sambhajinagar.

04

What can happen to a business if its supplements are found to be unsafe, misbranded or sold without the right licence?

The consequences depend on the violation. The FDA’s order lists improvement notices, licence suspension or cancellation, product seizures, recalls and criminal proceedings as possible actions. A business that operates without the required food licence also faces a penalty of up to ₹10 lakh. These measures can affect both a product’s sale and a company’s ability to continue operating.

For example, the FDA seized stock during inspections and sent samples to laboratories over suspicions that products were substandard, unsafe or misbranded. It said further legal action would follow when the food analyst’s report is received. The article does not state that the suspected products had already been conclusively found unsafe.

Businesses must obtain the relevant FSSAI licence, with the specific food category endorsed, and comply with product-label requirements. The FDA plans more risk-based inspections, including of sports nutrition, herbal and imported products, online sales and products supplied to hospitals. Findings and licence compliance could therefore shape what action follows.

05

What are health supplements and nutraceuticals, and how are they different from ordinary foods?

The article groups health supplements, nutraceuticals and special dietary foods under the FDA’s order but does not define them. In general usage, a health supplement is a product intended to add nutrients or other dietary ingredients to someone’s intake. Nutraceutical is a broad term for food or food-derived products presented as providing health benefits beyond basic nourishment. These general definitions are not definitions quoted from the article.

Ordinary foods are commonly eaten as part of a regular diet, while supplements are taken to add particular ingredients or meet a specific dietary purpose. Nutraceutical products may also be marketed around a stated health benefit. The distinction does not mean a product can claim to treat or prevent a disease; Maharashtra’s order prohibits those claims in advertisements.

The article says businesses making or selling these products need the relevant FSSAI licence, with the specific food category endorsed. Pharmacies and gyms also need a food licence or registration. The FDA’s inspections and planned checks cover several product types, including sports nutrition, weight-loss and herbal products.

06

What roles do Maharashtra’s FDA and India’s FSSAI play in regulating these products?

The Maharashtra FDA is the state agency carrying out the compliance order and enforcement drive described in the article. It issued the statewide order, conducted inspections, seized stock and sent samples for laboratory analysis. It can also take steps such as issuing improvement notices or suspending and cancelling licences.

FSSAI, the Food Safety and Standards Authority of India, is involved through licensing and product-category requirements. Businesses manufacturing or selling health supplements must hold the relevant FSSAI licence, with the specific food category endorsed. The FDA also reported finding two ingredients whose applications for product approval had been rejected by FSSAI.

The order applies to 1,100 existing licence holders in Maharashtra’s health supplement and nutraceutical categories. The FDA plans further risk-based inspections, including online sales and products supplied to hospitals. The article describes state enforcement and FSSAI requirements, but does not detail the full division of powers between the two agencies.

07

Why can a supplement’s claim to treat or prevent disease make it subject to rules that apply to medicines?

The article prohibits supplement advertisements from claiming that products treat, cure, mitigate or prevent disease. More generally, a product’s intended use can matter in deciding whether it is being presented as a food or as a medicine. A disease claim may therefore raise regulatory concerns beyond ordinary food marketing. This distinction is general background; the article does not set out a legal test for reclassification.

For instance, an ad saying that a powder prevents a disease would make a health promise that the FDA’s order expressly prohibits. Claims that products are clinically prescribed, or recommended by doctors or nutritionists, are also barred. These restrictions address the message presented to consumers, not simply the product’s name or ingredients.

The order took immediate effect across Maharashtra and applies throughout the supply chain. Misleading advertisements can attract a penalty of up to ₹10 lakh. The article does not say that every disease claim automatically makes a supplement subject to medicine rules; it reports the advertising ban and food-business requirements.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web